Baidu
map

Ardelyx重磅药物tenapanor(NHE3受体抑制剂)二期临床试验失利

2015-05-07 佚名 生物谷

生物医药公司的重心永远是药物,一个成功的药物能够帮助公司瞬间“登上人生巅峰”,而一旦失败,则会导致投资人避如蛇蝎。最近,Ardelyx医药公司就遭遇了这种痛苦。周二被迫宣布公司开发的重磅药物tenapanor在治疗三期慢性肾病和二型糖尿病的临床二期研究中遭遇滑铁卢,消息一出,投资者信心大减直接导致公司股票暴跌。 在这项有154名患者参与的临床二期研究中,tenapanor未能达到预期终点——

生物医药公司的重心永远是药物,一个成功的药物能够帮助公司瞬间“登上人生巅峰”,而一旦失败,则会导致投资人避如蛇蝎。最近,Ardelyx医药公司就遭遇了这种痛苦。周二被迫宣布公司开发的重磅药物tenapanor在治疗三期慢性肾病和二型糖尿病的临床二期研究中遭遇滑铁卢,消息一出,投资者信心大减直接导致公司股票暴跌。

在这项有154名患者参与的临床二期研究中,tenapanor未能达到预期终点——显著降低患者尿液中白蛋白-肌酸酐比例。数据显示,tenapanor治疗组患者这一比例降低了16%,而对照组则为11%,治疗组未能出现显著性差异。事实上,市场对于tenapanor的担忧由来已久。数周之前,Ardelyx公司公布了tenapanor治疗肠道易激综合症的临床二期研究,尽管治疗效果明显,但是由于许多患者出现了严重的腹泻症状,引起了众多投资者的隐忧。

如今这一消息无疑给tenapanor的前景更加雪上加霜。另一方面,公司在宣布此次临床二期研究失利的同时,也表示tenapanor的另一合作者阿斯利康公司目前正在分析此次研究数据,并将于下个月做出最终决定是否继续与Ardelyx公司在这一项目上的合作。阿斯利康公司在2012年与Ardelyx公司就tenapanor签订了价值2亿7千万美元的合作协议。如今看来,阿斯利康的耐性可能所剩不多。Ardelyx公司可能将独自进行tenapanor的开发工作。

tenapanor药物是一种肠道钠/质子交换器亚型3(NHE3)受体抑制剂,服用该药物的患者可以通过粪便(而不是尿液)排除体内多余的钠离子,从而降低肾病患者肾脏的负担。公司发言人表示,公司仍将继续探索tenapanor治疗慢性肾病和肠道易激综合症的可能性。这暗示着公司或许已经做好了与阿斯利康分道扬镳的准备。

原始出处:

AstraZeneca partner Ardelyx dives (again) as lead drug flunks PhII

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851243, encodeId=e415185124353, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 08 15:52:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036829, encodeId=8c6d203682908, content=<a href='/topic/show?id=c06f12e76a2' target=_blank style='color:#2F92EE;'>#NHE3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12776, encryptionId=c06f12e76a2, topicName=NHE3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Oct 24 05:52:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17270, encryptionId=63cd1e27025, topicName=Tenapanor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303f36951557, createdName=ying_wu, createdTime=Tue Apr 05 17:52:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679627, encodeId=930216e962742, content=<a href='/topic/show?id=2214960117d' target=_blank style='color:#2F92EE;'>#重磅药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96011, encryptionId=2214960117d, topicName=重磅药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bde27802965, createdName=qindq, createdTime=Sun May 17 02:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 02 04:52:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33728, encodeId=9a2733e28ae, content=希望能有好药品出来吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Wed Jul 29 10:43:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780007, encodeId=1d821e800074b, content=<a href='/topic/show?id=98312e33f6' target=_blank style='color:#2F92EE;'>#Ardelyx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2733, encryptionId=98312e33f6, topicName=Ardelyx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Sun Sep 13 18:52:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338136, encodeId=072113381361c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548794, encodeId=f3311548e94f8, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22900, encodeId=db83229005e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:18:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2016-01-08 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1851243, encodeId=e415185124353, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 08 15:52:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036829, encodeId=8c6d203682908, content=<a href='/topic/show?id=c06f12e76a2' target=_blank style='color:#2F92EE;'>#NHE3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12776, encryptionId=c06f12e76a2, topicName=NHE3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Oct 24 05:52:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17270, encryptionId=63cd1e27025, topicName=Tenapanor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303f36951557, createdName=ying_wu, createdTime=Tue Apr 05 17:52:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679627, encodeId=930216e962742, content=<a href='/topic/show?id=2214960117d' target=_blank style='color:#2F92EE;'>#重磅药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96011, encryptionId=2214960117d, topicName=重磅药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bde27802965, createdName=qindq, createdTime=Sun May 17 02:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 02 04:52:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33728, encodeId=9a2733e28ae, content=希望能有好药品出来吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Wed Jul 29 10:43:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780007, encodeId=1d821e800074b, content=<a href='/topic/show?id=98312e33f6' target=_blank style='color:#2F92EE;'>#Ardelyx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2733, encryptionId=98312e33f6, topicName=Ardelyx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Sun Sep 13 18:52:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338136, encodeId=072113381361c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548794, encodeId=f3311548e94f8, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22900, encodeId=db83229005e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:18:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2015-10-24 zhty5337
  3. [GetPortalCommentsPageByObjectIdResponse(id=1851243, encodeId=e415185124353, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 08 15:52:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036829, encodeId=8c6d203682908, content=<a href='/topic/show?id=c06f12e76a2' target=_blank style='color:#2F92EE;'>#NHE3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12776, encryptionId=c06f12e76a2, topicName=NHE3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Oct 24 05:52:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17270, encryptionId=63cd1e27025, topicName=Tenapanor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303f36951557, createdName=ying_wu, createdTime=Tue Apr 05 17:52:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679627, encodeId=930216e962742, content=<a href='/topic/show?id=2214960117d' target=_blank style='color:#2F92EE;'>#重磅药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96011, encryptionId=2214960117d, topicName=重磅药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bde27802965, createdName=qindq, createdTime=Sun May 17 02:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 02 04:52:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33728, encodeId=9a2733e28ae, content=希望能有好药品出来吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Wed Jul 29 10:43:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780007, encodeId=1d821e800074b, content=<a href='/topic/show?id=98312e33f6' target=_blank style='color:#2F92EE;'>#Ardelyx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2733, encryptionId=98312e33f6, topicName=Ardelyx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Sun Sep 13 18:52:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338136, encodeId=072113381361c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548794, encodeId=f3311548e94f8, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22900, encodeId=db83229005e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:18:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2016-04-05 ying_wu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1851243, encodeId=e415185124353, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 08 15:52:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036829, encodeId=8c6d203682908, content=<a href='/topic/show?id=c06f12e76a2' target=_blank style='color:#2F92EE;'>#NHE3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12776, encryptionId=c06f12e76a2, topicName=NHE3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Oct 24 05:52:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17270, encryptionId=63cd1e27025, topicName=Tenapanor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303f36951557, createdName=ying_wu, createdTime=Tue Apr 05 17:52:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679627, encodeId=930216e962742, content=<a href='/topic/show?id=2214960117d' target=_blank style='color:#2F92EE;'>#重磅药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96011, encryptionId=2214960117d, topicName=重磅药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bde27802965, createdName=qindq, createdTime=Sun May 17 02:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 02 04:52:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33728, encodeId=9a2733e28ae, content=希望能有好药品出来吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Wed Jul 29 10:43:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780007, encodeId=1d821e800074b, content=<a href='/topic/show?id=98312e33f6' target=_blank style='color:#2F92EE;'>#Ardelyx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2733, encryptionId=98312e33f6, topicName=Ardelyx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Sun Sep 13 18:52:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338136, encodeId=072113381361c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548794, encodeId=f3311548e94f8, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22900, encodeId=db83229005e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:18:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1851243, encodeId=e415185124353, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 08 15:52:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036829, encodeId=8c6d203682908, content=<a href='/topic/show?id=c06f12e76a2' target=_blank style='color:#2F92EE;'>#NHE3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12776, encryptionId=c06f12e76a2, topicName=NHE3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Oct 24 05:52:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17270, encryptionId=63cd1e27025, topicName=Tenapanor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303f36951557, createdName=ying_wu, createdTime=Tue Apr 05 17:52:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679627, encodeId=930216e962742, content=<a href='/topic/show?id=2214960117d' target=_blank style='color:#2F92EE;'>#重磅药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96011, encryptionId=2214960117d, topicName=重磅药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bde27802965, createdName=qindq, createdTime=Sun May 17 02:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 02 04:52:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33728, encodeId=9a2733e28ae, content=希望能有好药品出来吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Wed Jul 29 10:43:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780007, encodeId=1d821e800074b, content=<a href='/topic/show?id=98312e33f6' target=_blank style='color:#2F92EE;'>#Ardelyx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2733, encryptionId=98312e33f6, topicName=Ardelyx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Sun Sep 13 18:52:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338136, encodeId=072113381361c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548794, encodeId=f3311548e94f8, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22900, encodeId=db83229005e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:18:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1851243, encodeId=e415185124353, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 08 15:52:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036829, encodeId=8c6d203682908, content=<a href='/topic/show?id=c06f12e76a2' target=_blank style='color:#2F92EE;'>#NHE3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12776, encryptionId=c06f12e76a2, topicName=NHE3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Oct 24 05:52:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17270, encryptionId=63cd1e27025, topicName=Tenapanor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303f36951557, createdName=ying_wu, createdTime=Tue Apr 05 17:52:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679627, encodeId=930216e962742, content=<a href='/topic/show?id=2214960117d' target=_blank style='color:#2F92EE;'>#重磅药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96011, encryptionId=2214960117d, topicName=重磅药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bde27802965, createdName=qindq, createdTime=Sun May 17 02:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 02 04:52:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33728, encodeId=9a2733e28ae, content=希望能有好药品出来吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Wed Jul 29 10:43:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780007, encodeId=1d821e800074b, content=<a href='/topic/show?id=98312e33f6' target=_blank style='color:#2F92EE;'>#Ardelyx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2733, encryptionId=98312e33f6, topicName=Ardelyx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Sun Sep 13 18:52:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338136, encodeId=072113381361c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548794, encodeId=f3311548e94f8, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22900, encodeId=db83229005e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:18:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2015-07-29 sundong

    希望能有好药品出来吧

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1851243, encodeId=e415185124353, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 08 15:52:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036829, encodeId=8c6d203682908, content=<a href='/topic/show?id=c06f12e76a2' target=_blank style='color:#2F92EE;'>#NHE3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12776, encryptionId=c06f12e76a2, topicName=NHE3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Oct 24 05:52:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17270, encryptionId=63cd1e27025, topicName=Tenapanor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303f36951557, createdName=ying_wu, createdTime=Tue Apr 05 17:52:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679627, encodeId=930216e962742, content=<a href='/topic/show?id=2214960117d' target=_blank style='color:#2F92EE;'>#重磅药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96011, encryptionId=2214960117d, topicName=重磅药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bde27802965, createdName=qindq, createdTime=Sun May 17 02:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 02 04:52:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33728, encodeId=9a2733e28ae, content=希望能有好药品出来吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Wed Jul 29 10:43:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780007, encodeId=1d821e800074b, content=<a href='/topic/show?id=98312e33f6' target=_blank style='color:#2F92EE;'>#Ardelyx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2733, encryptionId=98312e33f6, topicName=Ardelyx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Sun Sep 13 18:52:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338136, encodeId=072113381361c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548794, encodeId=f3311548e94f8, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22900, encodeId=db83229005e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:18:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2015-09-13 yulin2006
  8. [GetPortalCommentsPageByObjectIdResponse(id=1851243, encodeId=e415185124353, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 08 15:52:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036829, encodeId=8c6d203682908, content=<a href='/topic/show?id=c06f12e76a2' target=_blank style='color:#2F92EE;'>#NHE3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12776, encryptionId=c06f12e76a2, topicName=NHE3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Oct 24 05:52:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17270, encryptionId=63cd1e27025, topicName=Tenapanor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303f36951557, createdName=ying_wu, createdTime=Tue Apr 05 17:52:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679627, encodeId=930216e962742, content=<a href='/topic/show?id=2214960117d' target=_blank style='color:#2F92EE;'>#重磅药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96011, encryptionId=2214960117d, topicName=重磅药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bde27802965, createdName=qindq, createdTime=Sun May 17 02:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 02 04:52:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33728, encodeId=9a2733e28ae, content=希望能有好药品出来吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Wed Jul 29 10:43:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780007, encodeId=1d821e800074b, content=<a href='/topic/show?id=98312e33f6' target=_blank style='color:#2F92EE;'>#Ardelyx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2733, encryptionId=98312e33f6, topicName=Ardelyx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Sun Sep 13 18:52:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338136, encodeId=072113381361c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548794, encodeId=f3311548e94f8, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22900, encodeId=db83229005e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:18:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1851243, encodeId=e415185124353, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 08 15:52:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036829, encodeId=8c6d203682908, content=<a href='/topic/show?id=c06f12e76a2' target=_blank style='color:#2F92EE;'>#NHE3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12776, encryptionId=c06f12e76a2, topicName=NHE3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Oct 24 05:52:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17270, encryptionId=63cd1e27025, topicName=Tenapanor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303f36951557, createdName=ying_wu, createdTime=Tue Apr 05 17:52:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679627, encodeId=930216e962742, content=<a href='/topic/show?id=2214960117d' target=_blank style='color:#2F92EE;'>#重磅药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96011, encryptionId=2214960117d, topicName=重磅药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bde27802965, createdName=qindq, createdTime=Sun May 17 02:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 02 04:52:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33728, encodeId=9a2733e28ae, content=希望能有好药品出来吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Wed Jul 29 10:43:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780007, encodeId=1d821e800074b, content=<a href='/topic/show?id=98312e33f6' target=_blank style='color:#2F92EE;'>#Ardelyx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2733, encryptionId=98312e33f6, topicName=Ardelyx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Sun Sep 13 18:52:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338136, encodeId=072113381361c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548794, encodeId=f3311548e94f8, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22900, encodeId=db83229005e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:18:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2015-05-09 xxxx1054
  10. [GetPortalCommentsPageByObjectIdResponse(id=1851243, encodeId=e415185124353, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Jan 08 15:52:00 CST 2016, time=2016-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036829, encodeId=8c6d203682908, content=<a href='/topic/show?id=c06f12e76a2' target=_blank style='color:#2F92EE;'>#NHE3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12776, encryptionId=c06f12e76a2, topicName=NHE3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec53439, createdName=zhty5337, createdTime=Sat Oct 24 05:52:00 CST 2015, time=2015-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1755546, encodeId=36541e55546a9, content=<a href='/topic/show?id=63cd1e27025' target=_blank style='color:#2F92EE;'>#Tenapanor#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17270, encryptionId=63cd1e27025, topicName=Tenapanor)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=303f36951557, createdName=ying_wu, createdTime=Tue Apr 05 17:52:00 CST 2016, time=2016-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679627, encodeId=930216e962742, content=<a href='/topic/show?id=2214960117d' target=_blank style='color:#2F92EE;'>#重磅药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96011, encryptionId=2214960117d, topicName=重磅药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bde27802965, createdName=qindq, createdTime=Sun May 17 02:52:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940390, encodeId=73f8194039064, content=<a href='/topic/show?id=3ec023929ce' target=_blank style='color:#2F92EE;'>#二期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23929, encryptionId=3ec023929ce, topicName=二期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jan 02 04:52:00 CST 2016, time=2016-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33728, encodeId=9a2733e28ae, content=希望能有好药品出来吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3ykRSkuxjt93yc9tvDWfIQItrwiaKSCps5kyrTyDlwic2FgoCWe88wR3ZiaggKYGueDIp26zVgnbzriaQ/0, createdBy=89d71602869, createdName=sundong, createdTime=Wed Jul 29 10:43:00 CST 2015, time=2015-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780007, encodeId=1d821e800074b, content=<a href='/topic/show?id=98312e33f6' target=_blank style='color:#2F92EE;'>#Ardelyx#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2733, encryptionId=98312e33f6, topicName=Ardelyx)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2a44345, createdName=yulin2006, createdTime=Sun Sep 13 18:52:00 CST 2015, time=2015-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338136, encodeId=072113381361c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2620, encryptionId=cd2a262068, topicName=APA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce072500140, createdName=12498b3em08(暂无昵称), createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548794, encodeId=f3311548e94f8, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat May 09 00:52:00 CST 2015, time=2015-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22900, encodeId=db83229005e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu May 07 21:18:00 CST 2015, time=2015-05-07, status=1, ipAttribution=)]
    2015-05-07 huaxipanxing

    看看

    0

相关资讯

The Lancet:2型糖尿病患者戒烟后风险更高?

    吸烟会增加患2型糖尿病的风险。然而,一些人口研究还表明,吸烟者戒烟3 - 5年后比继续吸烟者风险更高。经过10 - 12年的风险等同于从不吸烟者。小型队列研究表明,糖尿病患者控制在戒烟后的第一年暂时恶化。我们在一项人口研究中检测戒烟是否与糖尿病控制相关联,这种关联多久持续存在,并且这种关联是否是由重量变化介导的。    为此,我们使用健康促进网络(T

谁能最快跻身10亿俱乐部,捷诺维成功背后的女学霸

1921年,胰岛素的发现首次从分子层面揭开了糖尿病的秘密,且很快广泛应用于糖尿病的治疗。当时有媒体宣称,糖尿病会很快成为历史。但一个世纪即将过去,糖尿病仍在加速蔓延。显然,胰岛素并不是一劳永逸的万能良药。胰岛素用于治疗糖尿病虽然有效,但却无益于病人自身血糖调控系统的修复。虽然研究人员一直在努力,但是研发的药物仅能够在一定的程度上控制糖尿病的恶化,且副作用明显。因此,研发一个能够修复患者胰岛分泌

JAMA:母亲糖尿病与后代自闭症之间的关联

关于妊娠糖尿病和后代的自闭症谱系障碍(ASD)的联系是有限的,在怀孕期间对定时曝光的重要性没有报告。 为了评估自闭症风险与在子宫内暴露于预先存在的2型糖尿病和在GDM诊断相关的胎龄的妊娠期糖尿病(GDM)的关系。 这项回顾性纵向群组研究包括322323名在1995-2009年南加利福尼亚Kaiser Permanente(kpsc)医院出生的独生子女。孩子们通过从出生到第一出现下列情况而被追踪

J Periodontol:定量分析糖尿病与牙周炎之间的关系

大多数研究证据表明,糖尿病患者患牙周炎的几率更大,程度更重。此外,血糖控制在糖尿病与牙周炎之间起着重要的作用,血糖控制不佳与重度及广泛的牙周炎有关。该研究的目的是为了探讨(新西兰NZ)成年人群中糖尿病与牙周炎之间的关系。

STM:尿液分析预测肥胖及相关代谢疾病

在最近一项研究中,科学家们从肥胖人群的尿液样本中发现一些化合物分子,对于了解肥胖如何导致相关疾病发生提供了深入见解。   超重或肥胖是导致心脏疾病,中风,糖尿病和癌症发生的高风险因子,但将身体脂肪含量与疾病相关联的分子机制一直不清楚。   在这项研究中,研究人员发现肥胖个体的尿液样本中有一些可检测的"代谢性指标",靶向这些代谢物的生成过程或可减轻肥胖对相关疾病的影响

糖尿病患者要对动脉粥样硬化警觉

心血管疾病中,冠状动脉疾病(CAD)最为流行,而且是发达国家死亡的最大原因。根据DATASUS统计,巴西每年大约有100万的医院葬礼起因于心血管疾病。有一些特征和习惯,即风险因素,可能增加一个人患上动脉粥样硬化疾病的几率。在这些因素中,有总胆固醇(TC)和低密度脂蛋白(LDL)的升高, 较低水平的高密度脂蛋白(HDL)、动脉高血压(HAS),烟草的使用、肥胖、久坐不动、年纪大和糖尿病。科研出版社英

Baidu
map
Baidu
map
Baidu
map